Wedbush Comments on argenx’s Q2 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Equities researchers at Wedbush boosted their Q2 2025 earnings estimates for shares of argenx in a research report issued on Thursday, February 27th. Wedbush analyst D. Nierengarten now expects that the company will earn $4.22 per share for the quarter, up from their prior estimate of $4.15. Wedbush has a “Outperform” rating and a $655.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenx’s Q3 2025 earnings at $5.17 EPS, FY2025 earnings at $18.40 EPS and FY2028 earnings at $61.66 EPS.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

A number of other research firms have also weighed in on ARGX. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a report on Tuesday, November 12th. Evercore ISI raised their target price on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Deutsche Bank Aktiengesellschaft cut argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. Piper Sandler raised their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Finally, JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $662.83.

argenx Stock Down 0.2 %

Shares of NASDAQ:ARGX opened at $621.25 on Monday. The company has a market capitalization of $37.75 billion, a price-to-earnings ratio of -705.97 and a beta of 0.58. The company has a 50 day moving average of $642.51 and a two-hundred day moving average of $591.91. argenx has a 52-week low of $349.86 and a 52-week high of $678.21.

Hedge Funds Weigh In On argenx

Several institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp grew its stake in argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after buying an additional 1,170 shares during the last quarter. FMR LLC lifted its position in argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. boosted its stake in argenx by 64.0% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock valued at $1,311,000 after purchasing an additional 944 shares during the period. Stephens Inc. AR acquired a new position in argenx during the 4th quarter valued at about $310,000. Finally, Ritholtz Wealth Management grew its position in argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after purchasing an additional 414 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.